The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
The test detects and quantifies hepatitis C virus RNA and can be performed in approximately one hour.
Fleury will integrate IDbyDNA's Explify platform into its own laboratory workflow and develop a full suite of Explify-based clinical testing.
The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.
The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.
Mascots will distribute Lucence's blood-based tests, which detect DNA fragments shed by a tumor, in order to identify cancer-driving mutations.
The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.
In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.
The agreements involve the commercialization of the NeuMoDx 288 and 96 platforms for fully integrated, sample-to-answer, PCR-based molecular diagnostic testing.
The survey, conducted by SeraCare Life Sciences and GenomeWeb, asked more than 150 individuals working on clinical NGS about their quality control practices.
The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
Two thirds of families who attended enrollment sessions signed up, but those who did not voiced concerns about privacy, discrimination, and return of results.
Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
The firm plans to use the funds to develop a five-minute point-of-care molecular diagnostic system for multiplexed infectious disease detection.
The lab created active molecular identification tags to be able to track specimens themselves, rather than just their containers.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.